Last reviewed · How we verify

NCT05537909: ABSCESSBIOT

Role of Gut Microbiota in the Pathophysiology of Aseptic Abscesses

Status unknown NA Last updated 19 September 2024
What this trial tests

NA trial testing Biological sample collection in Aseptic Abscess Syndrome in 60 participants. Status unknown.

Timeline
7 September 2021
Primary endpoint
31 December 2024
31 December 2025

Quick facts

Lead sponsorUniversity Hospital, Clermont-Ferrand
PhaseNA
StatusStatus unknown
Study typeINTERVENTIONAL
Allocationnon randomized
Designparallel
Maskingnone
Primary purposediagnostic
Enrollment60
Start date7 September 2021
Primary completion31 December 2024
Estimated completion31 December 2025
Sites15 locations across France

Drugs / interventions tested

Conditions studied

Sponsor

University Hospital, Clermont-Ferrand

Who can join

18 and older, any sex, with Aseptic Abscess Syndrome. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

Aseptic abscess syndrome (AA) is a rare entity characterized by the occurrence of deep abscesses with no germ found. Antibiotic therapy is ineffective and they are sensitive to anti-inflammatory treatment with corticosteroids. Gut microbiota is important for the development of the immune system. In Crohn's disease which is frequently associated with AA syndrome, dysbiosis is found but could also be involved in the immune response at a distance from the gut. Stool, blood, saliva and urine samples will be taken from the patients included and their controls in the centers where they are followed. These biological samples will be transported to Clermont Ferrand using the same procedure (transporter and dry ice) where the following analyses will be performed: microbiota on stool and saliva, short chain fatty acids on stool and lymphocyte study on blood.

Publications & conference data

1 peer-reviewed publication reference this trial (live from Europe PMC):

  1. Host-microbiota relationship in the pathophysiology of aseptic abscess syndrome: protocol for a multicentre case-control study (ABSCESSBIOT).
    Trefond L, Billard E, Pereira B, Richard D, et al · · 2023 · cited 3× · PMID 37541750 · DOI 10.1136/bmjopen-2023-073776

Verify or expand the search:

Other trials of Biological sample collection

Trials testing the same drug.

Other University Hospital, Clermont-Ferrand trials

Trials by the same sponsor.

Verify against primary sources

Data sources for this page

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT05537909.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing